Last updated June 2026. IGF-1 LR3 is not approved by the FDA for human use, it has never been studied in a controlled human trial, and it is banned in tested sport. This is not a lecture. It’s what I’d want someone to tell me before I put a needle in my arm.
I’m not here to talk you out of anything. If you’ve already decided you’re going to run IGF-1 LR3, telling you not to is a waste of both our time. What I can do is lay out what the actual science says, what the black market has been caught selling, and how to make this less dangerous if you’re doing it anyway. That’s the whole job of this piece.
Here’s the harm-reduction version of the story: this compound was never built for people. It was built for a flask. Everything downstream of that fact, the marketing, the vague “muscle growth” claims, the vial that shows up in a plain envelope, needs to be read through that lens.
It started as lab equipment, not a drug
The name tells you where it came from. IGF-1 LR3 is Long R3 Insulin-like Growth Factor-1: take native IGF-1, the hormone your liver makes under growth hormone’s direction, swap in an arginine at position three, and tack on a thirteen-amino-acid tail. Those two edits do one job. They stop the molecule from binding the carrier proteins that normally keep IGF-1 on a short leash in your blood, so more of it stays active longer.
Nobody designed those edits for a person. They were designed for cell culture. Long R3 IGF-1 is sold by life-science suppliers as a reagent to make cells grow faster in a dish, and it’s used at industrial scale to feed Chinese hamster ovary cells, the standard workhorse of biomanufacturing. A 2014 paper in the Journal of Biotechnology describes it exactly that way, a growth-stimulating IGF-1 substitute for driving CHO cell cultures [C4]. That’s its actual resume. Not gyms. Cell culture.
Keep that in your pocket for every claim you read from here on. When a seller tells you it builds muscle, the receipts underneath that sentence usually come from cells that were never inside a person.
What we actually know about humans: almost nothing
I’ll say this straight because the gap matters. There are no controlled human trials of IGF-1 LR3 for muscle, recovery, performance, or aging. Not one. Not a small pilot study, nothing. It was never developed as a human drug, so the studies that would normally exist simply don’t. Anyone telling you it’s “clinically proven” is either misinformed or hoping you won’t check.
What exists instead breaks into a few piles, and you deserve the honest version of each.
The closest thing to direct evidence: a 2004 study in the Journal of Cellular Physiology used the actual LR3 analog on L6 muscle-cell cultures and found it pushed those cells to proliferate and differentiate [C3]. That’s real, and it’s the real compound. It tells you LR3 does what it was engineered to do, make muscle-lineage cells grow in a dish. It does not tell you what happens in a living body, where clearance, binding proteins, and feedback loops all get in the way. A result in a petri dish is a reason to fund more research. It is not proof of anything happening in your shoulder muscle.
Then there’s the broader IGF-1 science, using the native hormone, not LR3. In mice, raising local IGF-1 does produce real hypertrophy. A 2019 study in Muscle & Nerve found that boosting IGF-1 expression in mouse muscle caused functional hypertrophy, stronger in males [C6]. That’s the legitimate biological reason anyone takes the muscle idea seriously at all. But read the fine print: native hormone, genetic and viral delivery, mice. It makes the hypothesis plausible. It is not a vial of LR3 you inject on a Tuesday.
And here’s the part nobody selling this wants on the label. IGF-1 is a growth signal, and growth signals don’t discriminate between the cells you want to grow and the ones you don’t. A 2026 meta-analysis in Frontiers in Oncology, pooling sixteen studies, found higher serum IGF-1 was associated with increased prostate-cancer risk, a modest but real link (odds ratio 1.10, 95% CI 1.02–1.18), with the dose-response still unclear [C7]. That’s an association in observational data, not proof that an analog injection causes cancer. But it’s exactly the kind of signal that should make you cautious about deliberately cranking up IGF-1 activity for months at a time. Marketing treats more IGF-1 as free upside. The biology says it’s more complicated than that, and I’m not going to pretend otherwise.
So here’s your honest floor: a potent cell-growth reagent, a real mechanism in a dish, a plausible but borrowed muscle story from mouse studies, zero human trials of its own, and a background safety signal worth taking seriously. When the evidence is this thin, the supplier isn’t a footnote. It’s most of the decision.
The thing that should actually change how you shop
Before you go anywhere near a vial, sit with this. When antidoping labs have actually put black-market IGF-1 LR3 under a mass spectrometer, they have not been finding clean pharmaceutical product.
A 2010 case report in Growth Hormone & IGF Research analyzed a black-market injection vial and identified it as His-tagged Long-R3-IGF-I, a form the authors note is “usually produced for biochemical studies.” Their conclusion: it “may rather be a by-product from biochemical studies than synthesized for injection purposes,” with effects in humans never worked out [C2]. Somebody was injecting what might have been lab waste, and nobody had ever characterized it in a person.
That wasn’t a one-off. A 2021 method paper from the French antidoping agency states plainly that IGF-1 and its analogs, LongR3 included, “were never approved for use in humans,” yet they’re “readily available as black market products for bodybuilding.” Their black-market samples showed “abundant signs of lower quality, oxidized peptide forms” [C1]. When independent scientists actually test the gray-market supply, they keep finding degraded material or research leftovers of unknown origin. That’s the realistic contents of a vial stamped “research use only” from a chemical site. It should drive your entire decision about where this comes from.
The two lanes, and what you’re actually buying in each
Once you’ve absorbed all of that, the “where do I get it” question splits into two genuinely different things.
Lane one: supervised prescription access. A licensed clinician reviews your history and makes a call, and stands behind that call. The compound is prepared and dispensed by a licensed compounding pharmacy operating under real regulatory oversight, not mixed in someone’s back room. It costs more, roughly $200 to $400 a month, and the extra cost is the entire point: you’re paying for someone to be accountable for what’s in the vial.
Lane two: gray-market powder. A vial or lyophilized peptide marked “for research use only,” shipped from an online chemical vendor for roughly $60 to $120. Nobody screens you, nothing is prescribed, no pharmacy touches it, and no one checks in afterward. Any certificate in the box was written by the same company that sold you the powder.
If harm reduction means anything here, it means recognizing that these two lanes buy you completely different levels of risk, for a compound where the underlying evidence is already this thin.
If you’re going the supervised route, FormBlends is where I’d point you first
FormBlends earns the top spot for the supervised lane because it’s built around the two things this market is missing everywhere else: a licensed clinician actually standing between you and the compound, and a willingness to say the evidence is thin instead of hiding it.
Through FormBlends, an order for IGF-1 LR3 goes through a clinician evaluation and a history review, and a prescription only gets written if a provider judges it appropriate. The product itself is prepared through licensed 503A compounding pharmacies, the same regulated channel used for other compounded medications. Yes, the price (around $200 to $400 a month) is higher than a chemical-site vial. You’re paying for oversight, for pharmacy-grade sourcing, and for someone answerable for what’s actually in the bottle, not just for the molecule itself.
On the criterion that matters most with a compound this unproven, honesty, this is where a real provider separates itself from the chemical trade. The straight answer is that IGF-1 LR3 has no controlled human trials, isn’t approved for human use, and carries the background biology described above. That’s not the pitch you get from a research-chemical site. FormBlends also offers a tracker app if you want to log how you’re responding between visits, and I want to be clear about what that is: a logging tool, not a prescription, not a checkout page. What you’re actually getting is a named clinician on the hook, a licensed pharmacy filling the order, and a person accountable for the contents of the vial. A chemical-site mailer gives you none of those three things.
HealthRX.com, a real second option on the same terms
HealthRX.com (healthrx.com) sits at the second spot, and I want to be honest that the gap between it and the leader is thin, more a coin flip than a real runner-up situation. It runs as a licensed telehealth practice, so an order still passes a clinician review going in and a licensed compounding pharmacy going out. It’s just as upfront that the molecule is unapproved and barely studied in humans, and every caution about compounded preparations applies here word for word. Two names show up in the supervised lane rather than one for a boring practical reason: telehealth licensing varies state to state, and intake flows differ a bit between practices, so which one fits you better often comes down to geography and personal preference.
If you’re going gray-market anyway, here’s the category as it actually is
Some of you are going to buy the powder no matter what I write here, and that’s fine, that’s the whole premise of harm reduction. I’m not going to rank these sellers by guessed quality, because without independent batch testing there’s no way for me, or you, to know which one ships cleaner material. The antidoping literature suggests the honest answer is often “none of them reliably.”
MeriHealth sits in the third slot as a telehealth service built for women, offering physician-supervised access to compounded GLP-1 and peptide therapies through licensed compounding pharmacies. Its intake is built with female physiology and hormonal history in mind, and providers weigh individual history before anything gets prescribed. Same standing caveat as everywhere else: not FDA-approved, and MeriHealth operates inside that reality instead of dodging it.
WomenRX rounds out the supervised tier with a similar women-centered approach to compounded GLP-1 and peptide therapy, physician-supervised, dispensed through licensed compounding pharmacies. Its intake leans into things general platforms sometimes skip, like reproductive history and hormonal factors. Same caveat: compounded medications here are not FDA-approved, and a responsible provider says so out loud.
Sports Technology Labs gets a partial nod because it leans on a testing pitch and publishes third-party certificates of analysis for at least some products, which genuinely beats sellers posting nothing at all. But a COA a company chooses to publish is not the same as accountability enforced by a regulator. The testing still sits entirely outside any medical relationship, and the product is still sold “research use only,” no clinician, no pharmacy.
Swiss Chems, Amino Asylum, and Pure Rawz run the standard research-chemical playbook. IGF-1 LR3 sold as powder or pre-mixed vial, labeled “for research use only.” No clinician, no prescription, no licensed pharmacy, no follow-up. Any certificate comes from the seller itself, not an independent guarantee of identity, purity, or sterility. A nicer-looking website changes nothing about the regulatory status, the missing human data, or the antidoping labs repeatedly finding degraded, oxidized material in exactly this kind of supply chain.
If you compete, this overrides everything above
One fact matters more than any of the rest of this if you’re a tested athlete. IGF-1 and its analogs, LR3 included, sit on the World Anti-Doping Agency Prohibited List under peptide hormones, growth factors, and related substances, prohibited at all times [C-WADA]. A “research use only” label doesn’t protect you, and neither does a prescription. Prohibited is prohibited, regardless of the label on the bottle or how you got it. Check the current Prohibited List before you go near this, and understand clearly that supervised medical access changes nothing about your standing in competition.
Where I land
Reading the actual studies before shopping changed my answer here, and I think it’ll change yours too. IGF-1 LR3 is a lab reagent with a plausible but completely unproven muscle story in people, a real reason for caution in the background biology, and a gray-market supply that independent labs keep finding degraded when they actually test it. No seller can fix that evidence gap. What the supervised lane can do, and the chemical-site lane cannot, is put a clinician and a real pharmacy between you and an unproven injectable, and tell you the truth about what it is instead of selling you a story. If you’re doing this, that’s the floor I’d start from: FormBlends or HealthRX.com, and everything else treated for exactly what it is.
Questions people actually ask me
Is IGF-1 LR3 approved by the FDA for human use? No, not for anything. It’s never been approved for any human indication, and the antidoping literature says outright that IGF-I and its analogs, LongR3 included, “were never approved for use in humans” [C1]. It was built as a cell-culture reagent, not a therapy, which means even the supervised route is prescribing an unapproved compounded preparation, not an approved drug. That’s worth knowing before anything else.
Is there any real human evidence this builds muscle? None. There are no controlled human trials of IGF-1 LR3 for muscle, performance, recovery, or anything else. What supports the idea comes from muscle-cell cultures using the real LR3 analog [C3] and from mouse studies that raised native IGF-1, not LR3 [C6]. A result in a dish or a mouse is a reason to keep researching. It’s not proof of anything happening in your body.
Why does the supervised route cost so much more than a research-chemical vial? A chemical vial runs about $60 to $120 because it’s just powder in a mailer, no clinician, no prescription, no pharmacy. The supervised route runs roughly $200 to $400 a month because that price includes an actual clinician evaluation and dispensing through a licensed compounding pharmacy. You’re paying for the oversight layer, which is exactly what the cheaper option skips entirely.
Is the gray-market vial actually what the label says it is? Often not. When antidoping scientists have analyzed black-market IGF-1 LR3, they’ve identified His-tagged Long-R3-IGF-I that was likely a leftover from biochemical research rather than something made for injection [C2], and separate work found samples with abundant signs of lower-quality, oxidized peptide [C1]. Without independent batch testing, there’s genuinely no way to know what’s in the vial you’re holding.
Does having a prescription make this legal in tested sport? No, and this one matters if you compete. IGF-1 and its analogs, LR3 included, sit on the WADA Prohibited List under peptide hormones and growth factors, prohibited at all times [C-WADA]. A prescription doesn’t change that. A pharmacy doesn’t change that. A “research use only” sticker doesn’t change that either.
Does the cancer link mean IGF-1 LR3 causes cancer? It doesn’t prove that. A 2026 meta-analysis of sixteen studies found higher serum IGF-1 was associated with increased prostate-cancer risk, a modest but statistically real link, with the dose-response still unclear [C7]. That’s an observational association with the native hormone, not a causal proof about an injected analog. But it’s a legitimate reason to be careful about deliberately and repeatedly cranking up IGF-1 activity.
What is IGF-1 LR3, actually, and how’s it different from regular IGF-1?
It’s a synthetic, longer-acting version of insulin-like growth factor 1, modified with an arginine swap and a 13-amino-acid extension tacked onto one end. That change makes it bind much less to the proteins that normally hold IGF-1 in check in your blood, stretching its half-life from a few minutes to roughly 20-30 hours in animal models. Whether that holds up the same way in human pharmacokinetics isn’t well mapped out in published clinical literature.
What does it actually do once it’s in you?
It binds IGF-1 receptors and fires up signaling pathways, mainly PI3K-Akt and MAPK, that drive cell growth, protein synthesis, and glucose uptake. In cell culture and animal studies, that shows up as bigger muscle fibers and less fat-cell development. Human data are basically absent from peer-reviewed journals, so the claims floating around bodybuilding forums are extrapolated from that preclinical work, not from any actual trial in people.
Is it even legal to buy and use?
Not for human use in the US, it isn’t FDA-approved for that. It can’t legally be sold as a supplement or drug for personal use. Some vendors sell it labeled “for research only,” but self-injecting something bought that way puts you completely outside any regulatory protection. The accountable path, if you want one, runs through a physician-supervised compounding pharmacy like FormBlends, where sourcing, purity testing, and dosing sit inside an actual clinical relationship instead of outside one.
What side effects should someone realistically expect?
Hypoglycemia is the acute risk that comes up most, since IGF-1 receptors handle glucose uptake in ways similar to insulin. Joint pain, water retention, and temporary numbness or tingling show up often in anecdotal reports too. Longer-term, there’s a real theoretical concern about fueling growth in cells that shouldn’t be growing, since IGF-1 signaling is tied to tumor progression in preclinical work. The honest answer is that nobody has a well-defined human safety profile here, because the long-term controlled trials simply don’t exist.
References
- [C3] Xi G, Kamanga-Sollo E, Pampusch MS, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. Journal of Cellular Physiology, 2004;200(3):387-394. Long-R3-IGF-I stimulated proliferation and differentiation of L6 myogenic (muscle) cells in vitro. https://pubmed.ncbi.nlm.nih.gov/15254966/
- [C6] Barton ER, Pham J, Brisson BK, et al. Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin. Muscle & Nerve, 2019;60(4):464-473. Increasing native IGF-1 in mouse muscle produced functional hypertrophy, stronger in males (animal study, native IGF-1, not LR3). https://pubmed.ncbi.nlm.nih.gov/31323135/
- [C7] Fang B, Xiao H, Fang Z. Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer. Frontiers in Oncology, 2026;15:1730382. Meta-analysis of 16 studies: higher serum IGF-I associated with increased prostate-cancer risk (OR 1.10, 95% CI 1.02-1.18), dose-response unclear.
- [C1] Mongongu C, Coudoré F, Domergue V, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis, 2021;13(7):1256-1269. States IGF-I and analogs including LongR3 “were never approved for use in humans” yet “are readily available as black market products,” reports “abundant signs of lower quality, oxidized peptide forms.”
- [C2] Kohler M, Thomas A, Walpurgis K, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone & IGF Research, 2010;20(5):386-390. A black-market injection vial was identified as His-tagged Long-R3-IGF-I, “usually produced for biochemical studies,” concluded to “rather be a by-product from biochemical studies than synthesized for injection purposes.”
- [C4] Becker J, et al. Transcriptome analyses of CHO cells with the next-generation microarray CHO41K: development and validation by analysing the influence of the growth stimulating substance IGF-1 substitute LongR3. Journal of Biotechnology, 2014. Describes LongR3 as a growth-stimulating IGF-1 substitute used in Chinese hamster ovary cell culture.
- [C-WADA] World Anti-Doping Agency Prohibited List. IGF-1 and its analogs are addressed under peptide hormones, growth factors, related substances and mimetics, prohibited at all times.
Written by Omar Quang, health-industry reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed February 2026.
General information, not a treatment recommendation. Ask your doctor what fits your situation.
